{"entity":{"id":"immunebro-therapeutics","kind":"company","name":"ImmuneBro Therapeutics","aka":["Immunebro Therapeutics, Inc.","IMMUNEBRO THERAPEUTICS INC."],"tldr":"ImmuneBro Therapeutics in Chicago makes off-the-shelf immune cell treatments from healthy donors' T cells, combined with a T-cell engager, without gene editing. Its lead product, IBT1116, is being prepared for trials in B-cell cancers.","summary":"ImmuneBro Therapeutics develops allogeneic T cell products from healthy donor T cells that integrate T cell therapy with a T cell engager, avoiding genome editing and CAR engineering, according to the company. Its one lead asset, IBT1116, is at the IND-enabling stage for relapsed or refractory B-cell malignancies and relapse after CD19 CAR-T therapy. In fiscal year 2026 NCI awarded it USD 1,351,438 under SBIR award 2R44CA281523-02 for its engager T cell approach to off-the-shelf T cell therapy.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.immunebro.com/"},{"label":"NIH RePORTER: SBIR award 2R44CA281523-02","url":"https://reporter.nih.gov/project-details/11314650"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy","immunotherapy"],"technologies":["allogeneic-cell-therapy","t-cell-engager"],"targets":[],"drugs":["ibt1116"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on immunebro.com and NIH RePORTER on 4 November 2026."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"Chicago, IL","country":"US","companyType":"cell-therapy","website":"https://www.immunebro.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1351438,"source":"https://reporter.nih.gov/project-details/11314650","note":"NCI SBIR award (R44) 2R44CA281523-02: Engager T cell: A Simple Solution for \"Off-the-shelf\" T Cell Therapy for Cancer"}]},"route":"/companies/immunebro-therapeutics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"ibt1116","kind":"drug","name":"IBT1116","route":"/drugs/ibt1116/"}]}}